1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    













































































































































    Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist | American Journal of Neuroradiology  
    



















    































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      



          


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Review ArticleReview Article

  
      
Open Access

  
      
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
  
    	
J.D. Oldan, V.L. Jewells, B. Pieper and T.Z. Wong

  
    	
American Journal of Neuroradiology June 2021,  42 (6) 998-1007; DOI: https://doi.org/10.3174/ajnr.A7079 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵
    1. 

    2. Beach  TG, 
    3. Monsell  SE, 
    4. Phillips  LE, et al
    . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012;71:266–73 doi:10.1097/NEN.0b013e31824b211b pmid:22437338
    CrossRefPubMed
  2. 2.↵
    1. 

    2. Sala Frigerio  C, 
    3. De Strooper  B
    . Alzheimer's disease mechanisms and emerging roads to novel therapeutics. Annu Rev Neurosci 2016;39:57–79 doi:10.1146/annurev-neuro-070815-014015 pmid:27050320
    CrossRefPubMed
  3. 3.↵
    1. 

    2. Femminella  GD, 
    3. Thayanandan  T, 
    4. Calsolaro  V, et al
    . Imaging and molecular mechanisms of Alzheimer's disease: a review. Int J Mol Sci 2018;19:3702 doi:10.3390/ijms19123702 pmid:30469491
    CrossRefPubMed
  4. 4.↵
    1. 

    2. Reiman  EM, 
    3. Jagust  WJ
    . Brain imaging in the study of Alzheimer's disease. Neuroimage 2012;61:505–16 doi:10.1016/j.neuroimage.2011.11.075 pmid:22173295
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. 

    2. Arnold  M, 
    3. Nho  K, 
    4. Kueider-Paisley  A, et al
    . Sex and APOE4 genotype modify the Alzheimer's disease serum metabolome. Nat Commun 2020;11:1148 doi:10.1038/s41467-020-14959-w pmid:32123170
    CrossRefPubMed
  6. 6.↵
    1. 

    2. Rasmussen  MK, 
    3. Mestre  H, 
    4. Nedergaard  M
    . The glymphatic pathway in neurological disorders. Lancet Neurol 2018;17:1016–24 doi:10.1016/S1474-4422(18)30318-1 pmid:30353860
    CrossRefPubMed
  7. 7.↵
    1. 

    2. Hay  J, 
    3. Johnson  VE, 
    4. Smith  DH, et al
    . Chronic traumatic encephalopathy: the neuropathological legacy of traumatic brain injury. Annu Rev Pathol 2016;11:21–45 doi:10.1146/annurev-pathol-012615-044116 pmid:26772317
    CrossRefPubMed
  8. 8.↵
    1. 

    2. Tiepolt  S, 
    3. Patt  M, 
    4. Aghakhanyan  G, et al
    . Current radiotracers to image neurodegenerative disease. EJNMMI Radiopharm Chem 2019;4:17 doi:10.1186/s41181-019-0070-7 pmid:31659510
    CrossRefPubMed
  9. 9.↵
    1. 

    2. Yates  PA, 
    3. Desmond  PM, 
    4. Phal  PM, et al
    . AIBL Research Group. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology 2014;82:1266–73 doi:10.1212/WNL.0000000000000285 pmid:31659510
    CrossRefPubMed
  10. 10.↵
    1. 

    2. Barthélemy  NR, 
    3. Li  Y, 
    4. Joseph-Mathurin  N, et al
    . Dominantly Inherited Alzheimer Network. A soluable phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med 2020;26:398–407 doi:10.1038/s41591-020-0781-z pmid:32161412
    CrossRefPubMed
  11. 11.↵
    1. 

    2. Khosravi  M, 
    3. Newberg  A, 
    4. Alavi  A
    . Cognitive impairment and dementias. Semin Nucl Med 2018;48:498–512 doi:10.1053/j.semnuclmed.2018.07.005 pmid:30322476
    CrossRefPubMed
  12. 12.↵
    1. 

    2. Ibanez  V, 
    3. Pietrini  P, 
    4. Alexander  GE, et al
    . Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585–93 doi:10.1212/wnl.50.6.1585 pmid:9633698
    Abstract/FREE Full Text
  13. 13.↵
    1. 

    2. Ma  HR, 
    3. Sheng  LQ, 
    4. Pan  PL, et al
    . Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer's dementia: a meta-analysis. Transl Neurodegener 2018;7:9 doi:10.1186/s40035-018-0114-z pmid:29713467
    CrossRefPubMed
  14. 14.↵
    1. 

    2. Smailagic  N, 
    3. Lafortune  L, 
    4. Kelly  S, et al
    . 18F-FDG PET for prediction of conversion to Alzheimer's disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy. J Alzheimers Dis 2018;64:1175–94 doi:10.3233/JAD-171125 pmid:30010119
    CrossRefPubMed
  15. 15.↵
    1. 

    2. Martinez  G, 
    3. Vernooij  RW, 
    4. Fuentes  PP, et al
    . 18F-PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017;11:CD012216 doi:10.1002/14651858.CD012216.pub2 pmid:29164603
    CrossRefPubMed
  16. 16.↵
    1. 

    2. Morris  E, 
    3. Chalkidou  A, 
    4. Hammers  A, et al
    . Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2016;43:374–85 doi:10.1007/s00259-015-3228-x pmid:26613792
    CrossRefPubMed
  17. 17.↵
    1. 

    2. Johnson  KA, 
    3. Sperling  RA, 
    4. Gidicsin  CM, et al
    . AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9:S72–83 doi:10.1016/j.jalz.2012.10.007 pmid:23375563
    CrossRefPubMed
  18. 18.↵
    1. 

    2. Aizenstein  HJ, 
    3. Nebes  RD, 
    4. Saxton  JA, et al
    . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509–17 doi:10.1001/archneur.65.11.1509 pmid:19001171
    CrossRefPubMedWeb of Science
  19. 19.↵
    1. 

    2. Zukotynski  K, 
    3. Kuo  PH, 
    4. Mikulis  D, et al
    . PET/CT of dementia. AJR Am J Roentgenol 2018;211:246–59 doi:10.2214/AJR.18.19822 pmid:29949415
    CrossRefPubMed
  20. 20.↵
    1. 

    2. Ryan  NS, 
    3. Keihaninejad  S, 
    4. Shakespeare  TJ, et al
    . Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain 2013;136:1399–414 doi:10.1093/brain/awt065 pmid:23539189
    CrossRefPubMedWeb of Science
  21. 21.↵
    1. 

    2. Laforce  R   Jr., 
    3. Soucy  JP, 
    4. Sellami  L, et al
    . Molecular imaging in dementia: past, present, and future. Alzheimers Dement 2018;14:1522–52 doi:10.1016/j.jalz.2018.06.2855 pmid:30028955
    CrossRefPubMed
  22. 22.↵
    1. 

    2. Villemagne  VL, 
    3. Okamura  N
    . In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014;10:S254–64 doi:10.1016/j.jalz.2014.04.013 pmid:24924676
    CrossRefPubMed
  23. 23.↵
    1. 

    2. Hyman  BT, 
    3. Phelps  CH, 
    4. Beach  TG, et al
    . National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1–13 doi:10.1016/j.jalz.2011.10.007 pmid:22265587
    CrossRefPubMedWeb of Science
  24. 24.↵
    1. 

    2. Tanpitukpongse  TP, 
    3. Mazurowski  MA, 
    4. Ikhena  J, et al
    . Predictive utility of marketed volumentric software tools in subjects at risk for Alzheimer disease: do regions outside the hippocampus matter? AJNR Am J Neuroradiol 2017;38:546–52 doi:10.3174/ajnr.A5061 pmid:28057634
    Abstract/FREE Full Text
  25. 25.↵
    1. 

    2. Yueniwati  Y, 
    3. Wangsadjaja  C, 
    4. Yulidani  IG, et al
    . The role of brain MRI as an early detector of cognitive impairment. J Neurosci Rural Pract 2018;9:350–53 doi:10.4103/jnrp.jnrp_542_17 pmid:30069090
    CrossRefPubMed
  26. 26.↵
    1. 

    2. No  HJ, 
    3. Yi  HA, 
    4. Won  KS, et al
    . Association between white matter lesions and cerebral glucose metabolism in patient with cognitive impairment. Rev Esp Med Nucl Imagen Mol 2019;38:160–66 doi:10.1016/j.remn.2018.12.001 pmid:31053556
    CrossRefPubMed
  27. 27.↵
    1. 

    2. Chandra  A, 
    3. Dervenoulas  G, 
    4. Politis  M
    ; Alzheimer's Disease Neuroimaging Initiative. Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. J Neurol 2019;266:1293–1302 doi:10.1007/s00415-018-9016-3 pmid:30120563
    CrossRefPubMed
  28. 28.↵
    1. 

    2. Nasrabady  SE, 
    3. Rizvi  B, 
    4. Goldman  JE, et al
    . White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun 2018;6:22 doi:10.1186/s40478-018-0515-3 pmid:29499767
    CrossRefPubMed
  29. 29.↵
    1. 

    2. Belaidi  AA, 
    3. Bush  AI
    . Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem 2016;139(Suppl 1):179–97 doi:10.1111/jnc.13425 pmid:26545340
    CrossRefPubMed
  30. 30.↵
    1. 

    2. Gao  L, 
    3. Jiang  J, 
    4. Cai  Z, et al
    . Brain iron deposition analysis using susceptibility-weighted imaging and its association with body iron levels in patients with mild cognitive impairment. Mol Med Rep 2017;16:8209–15 doi:10.3892/mmr.2017.7668 pmid:28990041
    CrossRefPubMed
  31. 31.↵
    1. 

    2. Hohenfeld  C, 
    3. Werner  CJ, 
    4. Reetz  K
    . Resting-state connectivity in neurodegenerative disorders: Is there potential for an imaging biomarker. Neuroimage Clin 2018;18:849–70 doi:10.1016/j.nicl.2018.03.013 pmid:29876270
    CrossRefPubMed
  32. 32.↵
    1. 

    2. Li  HJ, 
    3. Hou  XH, 
    4. Liu  HH, et al
    . Towards systems neuroscience in mild cognitive impairment and Alzheimer's disease: a meta-analysis of 75 fMRI studies. Hum Brain Mapp 2015;36:1217–32 doi:10.1002/hbm.22689 pmid:25411150
    CrossRefPubMed
  33. 33.↵
    1. 

    2. Wilson  H, 
    3. Pagano  G, 
    4. Politis  M
    . Dementia spectrum disorders: lessons learnt from decades with PET research. J Neural Transm (Vienna) 2019;126:233–51 doi:10.1007/s00702-019-01975-4 pmid:30762136
    CrossRefPubMed
  34. 34.↵
    1. 

    2. Brown  RK, 
    3. Bohnen  NI, 
    4. Wong  KK, et al
    . Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics 2014;34:684–701 doi:10.1148/rg.343135065 pmid:24819789
    CrossRefPubMed
  35. 35.↵
    1. 

    2. Olney  NT, 
    3. Spina  S, 
    4. Miller  BL
    . Frontotemporal dementia. Neurol Clin 2017;35:339–74 doi:10.1016/j.ncl.2017.01.008 pmid:28410663
    CrossRefPubMed
  36. 36.↵
    1. 

    2. Diehl  J, 
    3. Grimmer  T, 
    4. Drzezga  A, et al
    . Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia: a PET study. Neurobiol Aging 2004;25:1051–56 doi:10.1016/j.neurobiolaging.2003.10.007 pmid:15212830
    CrossRefPubMedWeb of Science
  37. 37.↵
    1. 

    2. Grimmer  T, 
    3. Diehl  J, 
    4. Drzezga  A, et al
    . Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective 18F-FDG-PET study. Dement Geriatr Cogn Disord 2004;18:32–36 doi:10.1159/000077732 pmid:15084791
    CrossRefPubMedWeb of Science
  38. 38.↵
    1. 

    2. Diehl-Schmid  J, 
    3. Grimmer  T, 
    4. Drzezga  A, et al
    . Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging 2007;28:42–50 doi:10.1016/j.neurobiolaging.2005.11.002 pmid:16448722
    CrossRefPubMedWeb of Science
  39. 39.↵
    1. 

    2. Bocchetta  M, 
    3. Gordon  E, 
    4. Cardoso  MJ, et al
    . Thalamic atrophy in frontotemporal dementia: not just a C9orf72 problem. Neuroimage Clin 2018;18:675–81 doi:10.1016/j.nicl.2018.02.019 pmid:29876259
    CrossRefPubMed
  40. 40.↵
    1. 

    2. Jakabek  D, 
    3. Power  BD, 
    4. MacFarlane  MD, et al
    . Regional structural hypo- and hyper-connectivity of frontal-striatal and frontal-thalamic pathways in behavioral variant frontotemporal dementia. Hum Brain Mapp 2018;39:4083–93 doi:10.1002/hbm.24233 pmid:29923666
    CrossRefPubMed
  41. 41.↵
    1. 

    2. Sheela  KR, 
    3. Kesavadas  C, 
    4. Varghese  T, et al
    . Assessment of iron deposition in brain in frontotemporal dementia and its correlation with behavioral traits. AJNR Am J Neuroradiol 2017;38:1953–58 doi:10.3174/ajnr.A5339 pmid:28838910
    Abstract/FREE Full Text
  42. 42.↵
    1. 

    2. Farid  K, 
    3. Charidimou  A, 
    4. Baron  JC
    . Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update. Neuroimage Clin 2017;15:247–63 doi:10.1016/j.nicl.2017.05.002 pmid:28560150
    CrossRefPubMed
  43. 43.↵
    1. 

    2. Miller-Thomas  MM, 
    3. Sipe  AD, 
    4. Benzinger  TL, et al
    . Multimodality review of amyloid-related disease of the central nervous system. Radiographics 2016;36:1147–63 doi:10.1148/rg.2016150172 pmid:27399239
    CrossRefPubMed
  44. 44.↵
    1. 

    2. Werring  DJ, 
    3. Gregoire  SM, 
    4. Cipolotti  L
    . Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010;299:131–35 doi:10.1016/j.jns.2010.08.034 pmid:20850134
    CrossRefPubMed
  45. 45.↵
    1. 

    2. Jang  H, 
    3. Jang  YK, 
    4. Kim  HJ, et al
    . Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging 2019;46:1287–98 doi:10.1007/s00259-019-04314-7 pmid:30937462
    CrossRefPubMed
  46. 46.↵
    1. 

    2. Charidimou  A, 
    3. Farid  K, 
    4. Tsai  HH, et al
    . Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry 2018;89:410–17 doi:10.1136/jnnp-2017-316851 pmid:29070646
    Abstract/FREE Full Text
  47. 47.↵
    1. 

    2. Sarikaya  I
    . PET imaging in neurology: Alzheimer's and Parkinson's diseases. Nucl Med Commun 2015;36:775–81 doi:10.1097/MNM.0000000000000320 pmid:25920047
    CrossRefPubMed
  48. 48.↵
    1. 

    2. Shams  S, 
    3. Fallmar  S, 
    4. Schwarz  S, et al
    . MRI of the swallow tail sign: a useful marker in the diagnosis of Lewy body disease? AJNR Am J Neuroradiol 2017;38:1737–41 doi:10.3174/ajnr.A5274
    Abstract/FREE Full Text
  49. 49.↵
    1. 

    2. Eidelberg  D, 
    3. Moeller  JR, 
    4. Dhawan  V, et al
    . The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203–13 doi:10.1002/mds.870050304 pmid:2117706
    CrossRefPubMedWeb of Science
  50. 50.↵
    1. 

    2. Webb  J, 
    3. Willette  AA
    . Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity. Neurobiol Aging 2017;50:39–46 doi:10.1016/j.neurobiolaging.2016.10.006 pmid:27871051
    CrossRefPubMed
  51. 51.↵
    1. 

    2. Patro  SN, 
    3. Glikstein  R, 
    4. Hanagandi  P, et al
    . Role of neuroimaging in multidisciplinary approach towards non-Alzheimer's dementia. Insights Imaging 2015;6:531–44 doi:10.1007/s13244-015-0421-1 pmid:26206249
    CrossRefPubMed
  52. 52.↵
    1. 

    2. Bhattacharya  K, 
    3. Saadia  D, 
    4. Eisenkraft  B, et al
    . Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002;59:835–42 doi:10.1001/archneur.59.5.835 pmid:12020268
    CrossRefPubMedWeb of Science
  53. 53.↵
    1. 

    2. Belaidi  AA, 
    3. Bush  AI
    . Iron neurochemisty in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem 2016;139(Suppl 1):179–97 doi:10.1111/jnc.13425 pmid:26545340
    CrossRefPubMed
  54. 54.↵
    1. 

    2. Thomas  GE, 
    3. Leyland  LA, 
    4. Scahrag  AE, et al
    . Brain iron deposition is linked with cognitive severity in Parkinson's disease. J Neurol Neurosurg Psych 2020;0:1–8 doi:10.1136/jnnp-2019-322042 pmid:32079673
    CrossRefPubMed
  55. 55.↵
    1. 

    2. Surendranathan  A, 
    3. O'Brien  JT
    . Clinical imaging in dementia with Lewy bodies. Evid Based Ment Health 2018;21:61–65 doi:10.1136/eb-2017-102848 pmid:29602778
    Abstract/FREE Full Text
  56. 56.↵
    1. 

    2. McKeith  IG, 
    3. Boeve  BF, 
    4. Dickson  DW, et al
    . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017;89:88–100 doi:10.1212/WNL.0000000000004058 pmid:28592453
    Abstract/FREE Full Text
  57. 57.↵
    1. 

    2. McColgan  P, 
    3. Tabrizi  SJ
    . Huntington's disease: a clinical review. Eur J Neurol 2018;25(1):24–23 doi:10.1111/ene.13413 pmid:28817209
    CrossRefPubMed
  58. 58.↵
    1. 

    2. Agosta  F, 
    3. Altomare  D, 
    4. Festari  C, et al
    . EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. Eur J Nucl Med Mol Imaging 2018;45:1546–56 doi:10.1007/s00259-018-4033-0 pmid:29717332
    CrossRefPubMed
  59. 59.
    1. 

    2. Gaura  V, 
    3. Lavisse  S, 
    4. Payoux  P, et al
    . Association between motor symptoms and brain metabolism in early Huntingon disease. JAMA Neurol 2017;74:1088–96 doi:10.1001/jamaneurol.2017.1200 pmid:28672395
    CrossRefPubMed
  60. 60.↵
    1. 

    2. Pagano  G, 
    3. Niccolini  F, 
    4. Politis  M
    . Current status of PET imaging in Huntington's disease. Eur J Nucl Med Mol Imaging 2016;43:1171–82 doi:10.1007/s00259-016-3324-6 pmid:26899245
    CrossRefPubMed
  61. 61.↵
    1. 

    2. Caobelli  F, 
    3. Cobelli  M, 
    4. Pizzocaro  C, et al
    . The role of neuroimaging in evaluating patients affected by Creutzfeld-Jakob disease: a systematic review of the literature. J Neuroimaging 2015;25:2–13 doi:10.1111/jon.12098 pmid:24593302
    CrossRefPubMed
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
  
    	
J.D. Oldan, V.L. Jewells, B. Pieper, T.Z. Wong

  
    	
 American Journal of Neuroradiology Jun 2021, 42 (6) 998-1007; DOI: 10.3174/ajnr.A7079 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement